Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. Design and Sample Selection
2.3. Duration of Study
2.4. Instrument
2.5. Assessment of Storage LUTS and the Diagnosis of OAB
2.6. Statistical Analyses
3. Results
3.1. Demographic Characteristics
3.2. Urinary-Related AEs after COVID-19 Vaccination
3.3. Quantification of Urinary AEs with the Change of OABSS
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kadali, R.; Janagama, R.; Peruru, S.; Malayala, S.V. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int. J. Infect. Dis. 2021, 106, 376–381. [Google Scholar] [CrossRef] [PubMed]
- Dziedzic, A.; Riad, A.; Attia, S.; Klugar, M.; Tanasiewicz, M. Self-reported adverse events of COVID-19 vaccines in Polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST Project results in Central Europe. J. Clin. Med. 2021, 10, 5338. [Google Scholar] [CrossRef] [PubMed]
- Valera-Rubio, M.; Sierra-Torres, M.I.; García, R.C.; Cordero-Ramos, J.; López-Márquez, M.R.; Cruz-Salgado, O.; Calleja-Hernández, M.A. Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: A cross-sectional survey-based study in a Spanish hospital. Expert Rev. Vaccines 2022, 21, 533–540. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.W.; Lim, S.Y.; Lee, J.H.; Lim, J.S.; Kim, M.; Kwon, S.; Joo, J.; Kwak, S.H.; Kim, E.O.; Jung, J.; et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J. Korean Med. Sci. 2021, 36, e153. [Google Scholar] [CrossRef]
- Kadali, R.; Janagama, R.; Peruru, S.; Gajula, V.; Madathala, R.R.; Chennaiahgari, N.; Malayala, S.V. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J. Med. Virol. 2021, 93, 4420–4429. [Google Scholar] [CrossRef]
- Hsieh, S.M.; Liu, M.C.; Chen, Y.H.; Lee, W.S.; Hwang, S.J.; Cheng, S.H.; Ko, W.C.; Hwang, K.P.; Wang, N.C.; Lee, Y.L.; et al. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: Interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir. Med. 2021, 9, 1396–1406. [Google Scholar] [CrossRef]
- Hung, M.J.; Chou, C.L.; Yen, T.W.; Chuang, Y.C.; Meng, E.; Huang, S.T.; Kuo, H.C. Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. J. Formos. Med. Assoc. 2013, 112, 276–282. [Google Scholar] [CrossRef] [Green Version]
- Yamaguchi, O.; Nishizawa, O.; Takeda, M.; Yokoyama, O.; Homma, Y.; Kakizaki, H.; Obara, K.; Gotoh, M.; Igawa, Y.; Seki, N.; et al. Neurogenic Bladder Society. Clinical guidelines for overactive bladder. Int. J. Urol. 2009, 16, 126–142. [Google Scholar] [CrossRef]
- Watson, P. Stress, PTSD, and COVID-19: The utility of disaster mental health interventions during the COVID-19 pandemic. Curr. Treat. Options Psychiatry 2022, 9, 1–27, Advance online publication. [Google Scholar] [CrossRef]
- Mathieu, E.; Ritchie, H.; Ortiz-Ospina, E.; Roser, M.; Hasell, J.; Appel, C.; Giattino, C.; Rodés-Guirao, L. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 2021, 5, 947–953. [Google Scholar] [CrossRef]
- Taiwan Centers for Disease Control. Available online: https://www.cdc.gov.tw/File/Get/EEEdbzrFVdAFXPPteuGIVA (accessed on 5 April 2022).
- World Health Organization: Coronavirus Disease (COVID-19): Vaccines. What Are the Benefits of Getting Vaccinated. Available online: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(COVID-19)-vaccines (accessed on 5 April 2022).
- Zhao, H.; Souders, C.; Carmel, M.; Anger, J.T. Low rates of urologic side effects following coronavirus disease vaccination: An analysis of the Food and Drug Administration vaccine adverse event reporting system. Urology 2021, 153, 11–13. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Xu, K.; Hu, H.; Zhang, X.; Wang, X.; Na, Y.; Kang, X. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol. Urodyn. 2011, 30, 1448–1455. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Song, Y.; He, X.; Huang, H.; Xu, B.; Song, J. Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. Neurourol. Urodyn. 2006, 25, 717–721. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.S.; Lee, K.S.; Jung, J.H.; Han, D.H.; Oh, S.J.; Seo, J.T.; Lee, J.G.; Park, H.S.; Choo, M.S. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: Results of Korean EPIC study. World J. Urol. 2011, 29, 185–190. [Google Scholar] [CrossRef] [PubMed]
- Homma, Y.; Yamaguchi, O.; Hayashi, K.; Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005, 96, 1314–1318. [Google Scholar] [CrossRef] [PubMed]
- Zhu, J.; Hu, X.; Dong, X.; Li, L. Associations between risk factors and overactive bladder: A meta-analysis. Female Pelvic Med. Reconstr. Surg. 2019, 25, 238–246. [Google Scholar] [CrossRef]
- McGrother, C.W.; Donaldson, M.M.; Hayward, T.; Matthews, R.; Dallosso, H.M.; Hyde, C. Leicestershire MRC Incontinence Study Team. Urinary storage symptoms and comorbidities: A prospective population cohort study in middle-aged and older women. Age Ageing 2006, 35, 16–24. [Google Scholar] [CrossRef] [Green Version]
- Hirayama, A.; Torimoto, K.; Mastusita, C.; Okamoto, N.; Morikawa, M.; Tanaka, N.; Fujimoto, K.; Yoshida, K.; Hirao, Y.; Kurumatani, N. Risk factors for new-onset overactive bladder in older subjects: Results of the Fujiwara-kyo study. Urology 2012, 80, 71–76. [Google Scholar] [CrossRef]
- Semczuk-Kaczmarek, K.; Płatek, A.E.; Szymański, F.M. Co-treatment of lower urinary tract symptoms and cardiovascular disease—where do we stand? Cent. Eur. J. Urol. 2020, 73, 42–45. [Google Scholar] [CrossRef]
- Pan, X.; Liu, Y.; Bao, Y.; Wei, L.; Gao, Y. Changes of urinary proteomic before and after QIV and COVID-19 vaccination. bioRxiv 2022, 13, 1–8. [Google Scholar] [CrossRef]
- Siegrist, C.A. Mechanisms underlying adverse reactions to vaccines. J. Comp. Pathol. 2007, 137, S46–S50. [Google Scholar] [CrossRef] [PubMed]
- Tsiapakidou, S.; Apostolidis, A.; Pantazis, K.; Grimbizis, G.F.; Mikos, T. The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis. Int. Urogynecol. J. 2021, 32, 3143–3155. [Google Scholar] [CrossRef] [PubMed]
- Birder, L.; Andersson, K.E. Urothelial signaling. Physiol. Rev. 2013, 93, 653–680. [Google Scholar] [CrossRef] [Green Version]
- Creta, M.; Sagnelli, C.; Celentano, G.; Napolitano, L.; La Rocca, R.; Capece, M.; Califano, G.; Calogero, A.; Sica, A.; Mangiapia, F.; et al. SARS-CoV-2 infection affects the lower urinary tract and male genital system: A systematic review. J. Med. Virol. 2021, 93, 3133–3142. [Google Scholar] [CrossRef]
- Mumm, J.N.; Osterman, A.; Ruzicka, M.; Stihl, C.; Vilsmaier, T.; Munker, D.; Khatamzas, E.; Giessen-Jung, C.; Stief, C.; Staehler, M.; et al. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis? Eur. Urol. 2020, 78, 624–628. [Google Scholar] [CrossRef]
- Kaya, Y.; Kaya, C.; Kartal, T.; Tahta, T.; Tokgöz, V.Y. Could LUTS be early symptoms of COVID-19. Int. J. Clin. Pract. 2021, 75, e13850. [Google Scholar] [CrossRef]
- Angeli, F.; Spanevello, A.; Reboldi, G.; Visca, D.; Verdecchia, P. SARS-CoV-2 vaccines: Lights and shadows. Eur. J. Intern. Med. 2021, 88, 1–8. [Google Scholar] [CrossRef]
- Zou, X.; Chen, K.; Zou, J.; Han, P.; Hao, J.; Han, Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020, 14, 185–192. [Google Scholar] [CrossRef] [Green Version]
- Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.; et al. China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef]
- Varga, Z.; Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A.S.; Mehra, M.R.; Schuepbach, R.A.; Ruschitzka, F.; Moch, H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020, 395, 1417–1418. [Google Scholar] [CrossRef]
- Boni, A.; Cochetti, G.; Del Zingaro, M.; Paladini, A.; Turco, M.; Rossi de Vermandois, J.A.; Mearini, E. Uroflow stop test with electromyography: A novel index of urinary continence recovery after RARP. Int. Urol. Nephrol. 2019, 51, 609–615. [Google Scholar] [CrossRef] [PubMed]
- Gotoh, M.; Homma, Y.; Yokoyama, O.; Nishizawa, O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology 2011, 78, 768–773. [Google Scholar] [CrossRef] [PubMed]
Characteristics | All | OAB | Non-OAB | p-Value |
---|---|---|---|---|
Patients (n) | 889 | 71 | 818 | |
Sex | ||||
Male, n, % | 294 (33.07%) | 19 (26.77%) | 275 (33.62%) | 0.239 |
Female, n, % | 595 (66.93%) | 52 (73.23%) | 543 (66.38%) | 0.239 |
Age, n, % | 0.001 * | |||
<50 years | 686 (77.2%) | 44 (61.97%) | 642 (78.48%) | |
≥50 years | 203 (22.8%) | 27 (38.03%) | 176 (21.52%) | |
Comorbidity | ||||
Cardiovascular disease | 23 (2.59%) | 6 (8.45%) | 17 (2.08%) | 0.001 * |
Hypertension | 75 (8.4%) | 13 (18.31%) | 62 (7.58%) | 0.002 * |
Diabetes mellitus | 21 (2.4%) | 5 (7.04%) | 16 (1.96%) | 0.007 * |
Hyperlipidemia | 48 (5.4%) | 11 (15.49%) | 37 (4.52%) | <0.001 * |
Liver disease | 22 (2.47%) | 3 (4.23%) | 19 (2.32%) | 0.322 |
Type of vaccine | 0.529 | |||
viral-vector-based vaccine | 586 (65.9%) | 45 (63.4%) | 541 (66.1%) | |
mRNA-based vaccine | 260 (29.2%) | 24 (33.8%) | 236 (28.9%) | |
MVC COVID-19 vaccine | 43 (4.8%) | 2 (2.8%) | 41 (5.0%) | |
Baseline storage LUTS assessment | ||||
OABSS-Urgency, mean | 0.40 ± 0.87 | 2.85 ± 1.08 | 0.18 ± 0.40 | <0.001 * |
OABSS-Frequency, mean | 0.28 ± 0.50 | 0.79 ± 0.70 | 0.24 ± 0.46 | <0.001 * |
OABSS-Nocturia, mean | 0.57 ± 0.74 | 1.27 ± 0.93 | 0.50 ± 0.69 | <0.001 * |
OABSS-UUI, mean | 0.15 ± 0.47 | 0.72 ± 1.03 | 0.10 ± 0.34 | <0.001 * |
OABSS, mean | 1.39 ± 1.78 | 5.62 ± 2.12 | 1.02 ± 1.15 | <0.001 * |
Adverse Events | All n = 889 | OAB n = 71 | Non-OAB n = 818 | p-Value |
---|---|---|---|---|
Urinary symptoms | ||||
Urgency, n (%) | 54 (6.1%) | 10 (14.08%) | 44 (5.38%) | 0.030 * |
Frequency, n (%) | 49 (5.5%) | 8 (11.27%) | 41 (5.01%) | 0.027 * |
Nocturia, n (%) | 69 (7.8%) | 8 (11.27%) | 61 (7.46%) | 0.250 |
Urge urinary incontinence, n (%) | 19 (2.1%) | 1 (1.41%) | 18 (2.20%) | 0.658 |
Any storage LUTS, n (%) | 119 (13.4%) | 18 (25.35%) | 101 (12.35%) | 0.002 * |
Seek medical help due to urinary-related symptoms, n (%) | 49 (5.5%) | 12 (16.90%) | 37 (5.16%) | <0.001 * |
Generalized symptoms | ||||
Headache, n (%) | 309 (34.8%) | 24 (33.80%) | 285 (34.84%) | 0.860 |
Fever, n (%) | 371 (41.7%) | 25 (35.21%) | 346 (42.30%) | 0.245 |
Fatigue, n (%) | 492 (55.3%) | 32 (35.21%) | 460 (42.30%) | 0.070 |
Chills, n (%) | 207 (23.3%) | 13 (18.31%) | 194 (23.72%) | 0.301 |
Sore arm/injected site pain, n (%) | 602 (37.7%) | 45 (63.38%) | 566 (69.19%) | 0.311 |
Musculoskeletal symptoms | ||||
Arthritis/joint pains, n (%) | 122 (13.7%) | 13 (18.31%) | 109 (13.33%) | 0.243 |
Muscle pain, n (%) | 366 (41.2%) | 29 (40.85%) | 338 (41.32%) | 0.938 |
Scores | Pre-Vaccinated | Post-Vaccinated | Change in Scores | |||||
---|---|---|---|---|---|---|---|---|
OAB | Non-OAB | OAB | Non-OAB | OAB | Non-OAB | Total | p-value | |
(n = 71) | (n = 818) | (n = 71) | (n = 818) | (n = 71) | (n = 818) | (n = 889) | ||
OABSS-Urgency, mean | 2.85 ± 1.08 | 0.18 ± 0.40 | 2.97 ± 1.07 | 0.25 ± 0.56 | 0.13 ± 0.34 | 0.06 ± 0.42 | 0.07 ± 0.41 | 0.003 * |
OABSS-Frequency, mean | 0.79 ± 0.70 | 0.24 ± 0.46 | 0.90 ± 0.64 | 0.27 ± 0.48 | 0.11 ± 0.32 | 0.04 ± 0.22 | 0.04 ± 0.23 | 0.025 * |
OABSS-Nocturia, mean | 1.27 ± 0.93 | 0.50 ± 0.69 | 1.38 ± 0.95 | 0.58 ± 0.75 | 0.11 ± 0.32 | 0.08 ± 0.33 | 0.08 ± 0.33 | 0.209 |
OABSS-UUI, mean | 0.72 ± 1.03 | 0.10 ± 0.34 | 0.76 ± 1.10 | 0.11 ± 0.37 | 0.04 ± 0.36 | 0.01 ± 0.18 | 0.01 ± 0.12 | 0.099 |
Total OABSS, mean | 5.62 ± 2.12 | 1.02 ± 1.15 | 6.01 ± 2.18 | 1.22 ± 1.42 | 0.39 ± 0.80 | 0.19 ± 0.88 | 0.21 ± 0.88 | 0.014 * |
Variables | Change in OABSS | |||
---|---|---|---|---|
Crude OR (95% CI) | p-Value | Adjusted OR (95% CI) | p-Value | |
Sex, female | 1.473 (0.953–2.276) | 0.082 | 1.368 (0.873–2.142) | 0.171 |
Age | ||||
20–29 y | Ref. | Ref. | ||
30–39 y | 1.087 (0.603–1.958) | 0.782 | 1.073 (0.588–1.961) | 0.818 |
40–49 y | 1.463 (0.897–2.388) | 0.128 | 1.402 (0.837–2.350) | 0.199 |
50–59 y | 0.590 (0.306–1.138) | 0.115 | 0.601 (0.302–1.195) | 0.147 |
60–69 y | 1.068 (0.430–2.652) | 0.888 | 1.169 (0.433–3.152) | 0.758 |
≥70 y | 0.549 (0.070–4.307) | 0.568 | 0.576 (0.066–4.996) | 0.617 |
Comorbidity | ||||
Cardiovascular disease | 1.375 (0.460–4.113) | 0.569 | 1.090 (0.343–3.470) | 0.884 |
Hypertension | 0.645 (0.289–1.440) | 0.285 | 0.706 (0.290–1.718) | 0.443 |
Diabetes mellitus | 0.318 (0.042–2.390) | 0.265 | 0.372 (0.044–3.123) | 0.362 |
Hyperlipidemia | 0.742 (0.288–1.911) | 0.536 | 0.915 (0.324–2.579) | 0.866 |
Type of vaccine | ||||
viral-vector-based vaccine | Ref. | Ref. | ||
mRNA-based vaccine | 0.938 (0.610–1.442) | 0.770 | 0.913 (0.584–1.427) | 0.689 |
MVC COVID-19 vaccine | 0.639 (0.223–1.837) | 0.406 | 0.615 (0.211–1.791) | 0.373 |
Pre-vaccinated OAB | 2.411 (1.358–4.280) | 0.003 * | 2.552 (1.387–4.694) | 0.003 * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chen, Y.-C.; Liang, Y.-C.; Ho, S.-J.; Chen, H.-W.; Juan, Y.-S.; Tsai, W.-C.; Huang, S.-P.; Lee, J.-T.; Liu, Y.-P.; Kao, C.-Y.; et al. Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms? J. Clin. Med. 2022, 11, 2736. https://doi.org/10.3390/jcm11102736
Chen Y-C, Liang Y-C, Ho S-J, Chen H-W, Juan Y-S, Tsai W-C, Huang S-P, Lee J-T, Liu Y-P, Kao C-Y, et al. Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms? Journal of Clinical Medicine. 2022; 11(10):2736. https://doi.org/10.3390/jcm11102736
Chicago/Turabian StyleChen, Yu-Chen, Yin-Chi Liang, Shuo-Jung Ho, Hao-Wei Chen, Yung-Shun Juan, Wei-Chung Tsai, Shu-Pin Huang, Jung-Ting Lee, Yu-Peng Liu, Chung-Yao Kao, and et al. 2022. "Does COVID-19 Vaccination Cause Storage Lower Urinary Tract Symptoms?" Journal of Clinical Medicine 11, no. 10: 2736. https://doi.org/10.3390/jcm11102736